Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Pharma Equity Group A/S – indsigelse mod voldgiftskendelseOm Pharma Equity Group A/S
- Pharma Equity Group A/S – Challenge to Arbitral AwardAbout Pharma Equity Group A/S
- DelveInsight Business Research, LLPCommunity-Acquired Bacterial Pneumonia Market Poised for Expansion During the Forecast Period (2026-2036) Amid Rising Antimicrobial Resistance and Therapeutic Advances | DelveInsightThe community-acquired bacterial pneumonia market is poised for continued growth, driven by the substantial global disease burden, increasing hospitalization rates, an aging population, rising prevalence of comorbidities, and the growing challenge of antimicrobial resistance....
- CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS LawCAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
- Injectable Drug Delivery Market Forecast: USD 1,034.78 Billion by 2030 – MarketsandMarkets™MarketsandMarkets™ projects the global injectable drug delivery market will grow from USD 690.23 billion in 2025 to USD 1,034.78 billion by 2030, at a CAGR of 8.4% during the forecast period. Market growth is fueled by the rising prevalence of chronic diseases such as diabetes, cancer, cardiovascular diseases, and autoimmune disorders, increasing demand for biologics, advancements in injectable formulations, and the growing adoption of patient-friendly drug delivery devices including prefilled syringes, autoinjectors, pen injectors, wearable injectors, and needle-free systems.
- The Rosen Law Firm PAROSEN, A TOP RANKED LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff deadline.SO WHAT: If you purchased ARS Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
- The Korea HeraldMinistry of Food and Drug Safety of Korea, Successfully Concludes 'GBC 2026,' Marking a Great Leap in Bio– 5,600 participants from 19 countries discuss global bio innovation and the path forward – – Strengthened global regulatory cooperation, with a total of 23 meetings held with overseas regulators and industry, including 5 regulatory cooperation meetings – SEOUL, South Korea, Sept. 7, 2026...
- 复星医药宣布拟以不超过10亿港元回购H股，持续回馈股东Companies: Fosun International Limited（2026年9月6日，中国上海）—— 9月6日， 复星医药 宣布H股回购方案，计划以不超过10亿港元总金额回购H股股份，回购股份将注销或作为库存股持有。本次回购方案以实际行动回应市场关切，彰显公司管理层对公司内在价值的坚定信心，该方案已生效并将于即日起尽快推进实施。该计划亦为公司长期价值管理工具的延续运用，后续公司将结合市场情况动态评估、滚动实施，形成常态化股东回报机制。 2026年上半年，复星医药盈利质量持续向好，创新药品与海外收入占比稳步提升，核心经营指标在2025年基础上进一步夯实。 营业收入：204.42亿元，同比增长 4.75%； 扣非归母净利润：11.44亿元，同比增长 19.09%； 经营性现金流：24.24亿元，同比增长 13.59%。 本次回购资金主要来源于减持Gland Pharma约6.00%股份所得（交易总对价约2.94亿美元）。交易完成后，复星医药仍为Gland Pharma控股股东，持股约45.76%
- Ascendis PharmaAscendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress of the European Society for Paediatric Endocrinology (ESPE) being held September 8-10, 2026, in Marseille, France. Updates will include a podium presentation of the first sentinel cohort data from the pivotal reACHin Trial of TransCon CNP (navepegritide) in infants with achondroplasia aged 0 to <2 years.
- Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modificationCompanies: Novo NordiskSTEP Young data show 40.4% of children treated with semaglutide and lifestyle modification were no longer classified as having obesity.
- $321 Million Global Stem Cell Therapy Market Forecast to Quadruple in Size During 2026-2035 - Expansion of Expedited Regulatory Pathways for Advanced Therapies Driving GrowthThe "Stem Cell Therapy Market by Source of Stem Cell, Origin of Stem Cell, Type of Stem Cell, Lineage of Stem Cell, Route of Administration, Therapeutic Area, End Users and Geographical Regions - Trends and Global Forecast Till 2035" has been added to ResearchAndMarkets.com's offering.
- CelluPro Receives EXCiPACT™ Certification for GMP-grade Cell Culture Media Manufacturing, Strengthening Global Biomanufacturing Supply CapabilitiesCelluPro, a biotechnology company specializing in serum-free cell culture media and bioprocess solutions, has achieved EXCiPACT™ GMP Certification for Pharmaceutical Auxiliary Materials (PAMs), becoming the first Chinese cell culture media...